12/30/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Topogyne

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
3 3
3 3

Misoprostol

Misoprostol

Klass : 3

Visa all info

Skriv ut

Kontakta oss

  1. Fonseca W, Alencar AJ, Pereira RM, Misago C. Congenital malformation of the scalp and cranium after failed first trimester abortion attempt with misoprostol. Clin Dysmorphol. 1993;2:76-80.

  2. Marques-Dias MJ, Gonzalez CH, Rosemberg S. Mobius sequence in children exposed in utero to misoprostol: Neuropathological study of three cases. Birth Defects Research Part A 2003;67:1002-7.

  3. Coelho KE, Sarmento MF, Veiga CM, Speck-Martins CE, Safatle HP, Castro CV et al. Misoprostol embryotoxicity: Clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet 2000;95:297-301.

  4. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugamaya SM et al. Prenatal exposure to misoprostol and vascular disruption defects: A case-control study. Am J Med Genet 2000;95:302-6.

  5. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000;107:519-23.

  6. Adam MP, Manning MA, Beck AE, Kwan A, Enns GM, Clericuzio C et al. Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion. Am J Med Genet A 2003;123(1):72-8.

  7. Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol 2005;105(5Pt2):1203-5.

  8. Gonzalez CH, Marques-Dias MJ, Kim CA et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998;351:1624-7.

  9. Pastuszak AL, Schuler L, Speck-Martins CE et al. Use of misoprostol during pregnancy and Mobius' syndrome in infants. N Engl J Med 1998;338:1881-5.

  10. da Silva Dal Pizzol T, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol. 2006;22:666-71.

  11. Schuler L, Pastuszak A, Sanseverino TV et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 1999;13:147-51.

  12. Misoprostol and Teratogenicity: Reviewing the Evidence. Population Council may 2003 New York [www]. [cited 2012-06-01]. http://gynuity.org/downloads/mtg_rep_miso_teratogen_en.pdf

  13. Andersen JT, Mastrogiannis D, Andersen NL, Petersen M, Broedbaek K, Cejvanovic V et al. Diclofenac/misoprostol during early pregnancy and the risk of miscarriage: a Danish nationwide cohort study. Arch Gynecol Obstet. 2016;294:245-50.

  14. Blanch G, Quenby S, Ballantyne ES et al. Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study. BMJ 1998;316:1712-3.

  1. Fonseca W, Alencar AJ, Pereira RM, Misago C. Congenital malformation of the scalp and cranium after failed first trimester abortion attempt with misoprostol. Clin Dysmorphol. 1993;2:76-80.
  2. Marques-Dias MJ, Gonzalez CH, Rosemberg S. Mobius sequence in children exposed in utero to misoprostol: Neuropathological study of three cases. Birth Defects Research Part A 2003;67:1002-7.
  3. Coelho KE, Sarmento MF, Veiga CM, Speck-Martins CE, Safatle HP, Castro CV et al. Misoprostol embryotoxicity: Clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet 2000;95:297-301.
  4. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugamaya SM et al. Prenatal exposure to misoprostol and vascular disruption defects: A case-control study. Am J Med Genet 2000;95:302-6.
  5. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000;107:519-23.
  6. Adam MP, Manning MA, Beck AE, Kwan A, Enns GM, Clericuzio C et al. Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion. Am J Med Genet A 2003;123(1):72-8.
  7. Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol 2005;105(5Pt2):1203-5.
  8. Gonzalez CH, Marques-Dias MJ, Kim CA et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998;351:1624-7.
  9. Pastuszak AL, Schuler L, Speck-Martins CE et al. Use of misoprostol during pregnancy and Mobius' syndrome in infants. N Engl J Med 1998;338:1881-5.
  10. da Silva Dal Pizzol T, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol. 2006;22:666-71.
  11. Schuler L, Pastuszak A, Sanseverino TV et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 1999;13:147-51.
  12. Misoprostol and Teratogenicity: Reviewing the Evidence. Population Council may 2003 New York [www]. [cited 2012-06-01]. http://gynuity.org/downloads/mtg_rep_miso_teratogen_en.pdf
  13. Andersen JT, Mastrogiannis D, Andersen NL, Petersen M, Broedbaek K, Cejvanovic V et al. Diclofenac/misoprostol during early pregnancy and the risk of miscarriage: a Danish nationwide cohort study. Arch Gynecol Obstet. 2016;294:245-50.
  14. Blanch G, Quenby S, Ballantyne ES et al. Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study. BMJ 1998;316:1712-3.